|Day Low/High||3.49 / 3.81|
|52 Wk Low/High||2.55 / 7.45|
After finding success in treatment for epilepsy and other conditions, some in the industry are focusing on autism spectrum disorder.
The charts make ZYNE look bearish and not particularly attractive, so avoid.
Market players are more skeptical of the quick moves on U.S.-China trade news.
Without Apple doing so well Monday the indices would look much different.
It's tough to do much while we await major news events.
This sort of insider activity often coincides with a turnaround in these types of beaten down equities.
It is time for investors to start differentiating between the Good, the Bad and the Ugly in cannabis stocks.
The milestone approval of Epidiolex bodes well for cannabis-based drug stocks GW Pharma, Nemus, Zynerba and Insys.
It's a simple option strategy to mitigate some risk in deploying new funds.
Some minor improvement in the major indices from our last update. Market is almost to flat line as we approach the close of the week -- and June options expiration, as well. Whole Foods Market is slightly above the $42 a share buyout offer from Ama...
Growth is almost guaranteed in these two areas, says James McDonald of Index Strategy Advisors.
This small-cap has 2 intriguing medicinal compounds under development.